Source: ForexTV

Zosano Pharma: Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta

-FDA feedback consistent with FDA's preliminary communication in September- -Company requesting meeting with FDA to discuss next steps required to resubmit the NDA- FREMONT, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) - Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, announced today that it has received a complete response letter (CRL) from the U.S. Food and ...The post Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta appeared first on ForexTV.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating

83/100

Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more